These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22315486)

  • 1. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
    Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
    Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
    Barnes JA; Jacobsen E; Feng Y; Freedman A; Hochberg EP; LaCasce AS; Armand P; Joyce R; Sohani AR; Rodig SJ; Neuberg D; Fisher DC; Abramson JS
    Haematologica; 2013 Apr; 98(4):615-9. PubMed ID: 23144193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
    Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA
    Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
    Witzig TE; Reeder CB; LaPlant BR; Gupta M; Johnston PB; Micallef IN; Porrata LF; Ansell SM; Colgan JP; Jacobsen ED; Ghobrial IM; Habermann TM
    Leukemia; 2011 Feb; 25(2):341-7. PubMed ID: 21135857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
    Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
    J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
    Tobinai K; Ogura M; Maruyama D; Uchida T; Uike N; Choi I; Ishizawa K; Itoh K; Ando K; Taniwaki M; Shimada N; Kobayashi K
    Int J Hematol; 2010 Nov; 92(4):563-70. PubMed ID: 20972652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
    Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
    Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
    Ansell SM; Tang H; Kurtin PJ; Koenig PA; Inwards DJ; Shah K; Ziesmer SC; Feldman AL; Rao R; Gupta M; Erlichman C; Witzig TE
    Lancet Oncol; 2011 Apr; 12(4):361-8. PubMed ID: 21440503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
    Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
    Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
    Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
    Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
    Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
    N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
    Ghobrial IM; Witzig TE; Gertz M; LaPlant B; Hayman S; Camoriano J; Lacy M; Bergsagel PL; Chuma S; DeAngelo D; Treon SP
    Am J Hematol; 2014 Mar; 89(3):237-42. PubMed ID: 24716234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
    Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
    Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.